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Introduction
Acute graft-versus-host disease (aGVHD) is the main
complication of hematopoietic stem cell transplantation
(HSCT) and is an important cause of mortality after
HSCT. Regulatory T cells (Treg) therapy has proven
highly effective in experimental mouse models of GVHD;
however, translation of this approach into humans has
been difficult because of the identification of several dis-
tinct subsets of human Treg and the observation that an
inflammatory environment may cause conversion of
human Treg into effector Th17 cells.
Results
Based on the expression of CD45RA and HLADR, we have
identified three different subsets of human FOXP3+ Treg
in peripheral blood or cord blood, which present suppres-
sive activity in vitro. Gene expression profiling combined
with global pathway analysis revealed clearly distinct
immune signatures for each subset, which were validated
by analysis at the single-cell level. Single-cell gene profiling
also revealed a striking heterogeneity of gene expression
within these Treg subpopulations and that cytokine-
expressing Treg did not downregulate FOXP3 and other
Treg markers.
We prospectively studied Treg subsets in alloHSCT reci-
pients’ peripheral blood. We found that percentages of
FOXP3+ cells were not significantly different in aGVHD
patients and in the control group. However, a strong
alteration of Treg subsets was observed in the aGVHD
group compared to the control group, with a pronounced
bias towards an activated phenotype, while naïve Treg
were almost absent. Gene expression analysis of the three
populations at the single-cell level shows a stable expres-
sion of Tregs markers.
Conclusion
As human Tregs constitute a heterogeneous population,
the analysis of specific Treg subsets frequencies rather
than total pool of CD4+FOXP3+ Treg frequency may be
more refined. We propose that an excess of activated
Tregs may serve as biomarker for aGVHD.
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